Open Access Biomedical Publisher Using Post Publication Peer Review
A revised version of this paper has been submitted and will be available for review until November 6, 2011, this Sunday-coming. This paper has been revised courtesy of the 16 reviewers whose comments were accepted and contributed to the quality of a very important manuscript.
Thank you all for you brilliant contributions,
Bill Misner PhD
From the reviewer's input, a final verson of this Case Report has been revised and submitted for review within the next 24-48 hours.
The title was changed to "Coenzyme Q10 Effects Endurance Running Performance - A Case Report."
I am deeply in debt to the reviewers for their remarkable counsel and brilliant critique.
Thank you for presenting most excellent reviews with guiding constructive comments... I agree with almost all the comments completely. Some comments were less than constructive, and did not add to evaluating the merit of a "Case Report." Single-Subject "Case Reports" are always inconclusive and can only present objective information-observations that if adequate "May" call for reliable "Studies" with proper controls to determine the differences between hypothesis and conclusions with statistical significance support.Prior to the test trials, I prepared by reading the science written by the scientists working for both manufacturers. Each argued with each other to a stalemate. The Kaneka rationale matched some science-method reports connected with aging, while Best Formulations rationale stated that Ubiqiunone was more stable than Ubiquinol, and that stability for the exogenous form favored Ubiquinone and that they each wereinvolved interchangeably and needed for trading off hydrogen molecules during the energy cycle. Both manufacturers stated that their product maintained steady state blood serum levels better than the other. Who was I to believe? I therefore hypothesized that if I took 400mg/day of either Ubiquinol or Ubiquinone during 90-days of timed runs over a common course that I had trained on to attain familiarity and fitness, that one or both versions would exceed base performance, determined after a 14-day washout period (half-life of CoQ10 is 36-72 hours) in a resting subject) and since I was training during the washout period 60-90 minutes average daily, the washout 14-days would easily washout all previously dosed CoQ10. The methods section of this paper did not detail that prior to each timed trial, resting heart rate the day prior to each test was between 51-56 bpm. (resting low HR =51bpm). If the resting heart rate was not within this range, recovery being incomplete, no timed run performance was determined. Max Heart Rate for a 71-y male based on the Karvonnen formula, is 149 bpm. Heart rate at the end of each timed performance ranged between 156-164 (104%-110% max heart rate).This is a clear indication that on the day a timed performance was tested, the subject was adequately rested and at finish had expended himself to the full. I have no connection with or competing interest in either form of product and am persuaded that bias was absent. Nevertheless, double blind and placebo would and should be employed to address the issue of bias. The first paper proceeding this one's title was changed from "Case Study" to "Case Report." Physicians write Case Reports regularly reporting an anomaly in detail based on their objective and many times subjective observations, without placebo, nocebo, or blinded protocol structure. A "Case Report" several of the reviewers stated precedes or justifies tightening double-blinded and placebo protocols to control for the sake of responsibly collecting data for determining conclusions. This "Case Report" is an open label experiment in which the author was the subject who strictly maintained the same low fat whole plant food dietary menu during the year prior to and the year of these 21-timed performances collected during this 194-day period. In my view, this "Case Report," though inconclusive as based on sound science method principles, presents specific information observed and reported by an one elderly fit 71-year subject for recruiting a larger contingent of adult male and female fit subjects to measure and evaluate the effects of Ubiquinone or Ubiquinol in double-blind-placebo on timed endurance performance. The question asked is, does this "Case Report" merit a larger study with proper controls to ensure reliability? The answer is absolutely, yes!Respectfully submitted, with gratitude for all your reviews,Bill Misner PhD
All site content, except where otherwise noted, is licensed under a
Creative Commons Attribution License